PRESS RELEASE
News
-
-
PRESS RELEASE
Capital B confirms the acquisition of 48 BTC for EUR4.7 million, the holding of a total of 2,249 BTC, and a BTC Yield of 1,536.6% YTD
Capital B confirms final completion of capital increase agreements with TOBAM and Fulgur Ventures, enabling acquisition of additional bitcoins. BTC Yield 1536.6% YTD, BTC Gain of 614.6, BTC € Gain of €60.6 million -
-
PRESS RELEASE
Trade Republic expands from Brokerage to Wealth Management – Invest into Private Markets from 1 euro. Start of strategic partnership with Apollo and EQT.
Trade Republic expands from Brokerage to Wealth Management, partnering with Apollo and EQT. Customers can invest in Private Markets from 1 euro, offering unique diversification. Strategic move to democratize private investing for all European investors -
PRESS RELEASE
Résultats annuels 2024-2025 et perspectives ambitieuses - Evolution en cours au sein de la Gouvernance
Agripower France annonce des résultats annuels en amélioration malgré des éléments non récurrents. Signature de nouveaux contrats pour développer l'injection biométhane. Objectif CA confirmé avec projet d'augmentation de capital -
-
PRESS RELEASE
Curatis: Double-digit growth in core business and development milestone achieved for C-PTBE-01
Curatis Holding AG reports double-digit revenue growth in H1 2025, signing a significant partnership with Phoenix Labs for C-PTBE-01. Financials show a loss due to increased development expenses for corticorelin -
-
REGULATED PRESS RELEASE
Biophytis obtient un financement public au Brésil pour l’essai de Phase 2 dans l’obésité et signe des accords avec des centres cliniques locaux de premier plan
Biophytis obtient un financement public et signe des accords pour l'essai de Phase 2 dans l'obésité au Brésil, renforçant ainsi son programme et sa valeur pour les investisseurs -
REGULATED PRESS RELEASE
Biophytis Secures public funding in Brazil for Obesity Phase 2 Trial and Signs Agreements with Leading local Clinical Partners
Biophytis secures public funding in Brazil for Obesity Phase 2 trial and signs agreements with leading local clinical partners, strengthening its OBA Phase 2 program and obtaining non-dilutive funding support through EMBRAPII
